全文获取类型
收费全文 | 6458篇 |
免费 | 400篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 472篇 |
妇产科学 | 198篇 |
基础医学 | 659篇 |
口腔科学 | 96篇 |
临床医学 | 497篇 |
内科学 | 1116篇 |
皮肤病学 | 99篇 |
神经病学 | 659篇 |
特种医学 | 259篇 |
外科学 | 1129篇 |
综合类 | 221篇 |
一般理论 | 5篇 |
预防医学 | 361篇 |
眼科学 | 184篇 |
药学 | 391篇 |
中国医学 | 23篇 |
肿瘤学 | 464篇 |
出版年
2023年 | 47篇 |
2022年 | 91篇 |
2021年 | 188篇 |
2020年 | 95篇 |
2019年 | 140篇 |
2018年 | 210篇 |
2017年 | 122篇 |
2016年 | 163篇 |
2015年 | 178篇 |
2014年 | 267篇 |
2013年 | 298篇 |
2012年 | 432篇 |
2011年 | 428篇 |
2010年 | 279篇 |
2009年 | 226篇 |
2008年 | 382篇 |
2007年 | 380篇 |
2006年 | 304篇 |
2005年 | 332篇 |
2004年 | 306篇 |
2003年 | 259篇 |
2002年 | 217篇 |
2001年 | 165篇 |
2000年 | 159篇 |
1999年 | 113篇 |
1998年 | 54篇 |
1997年 | 41篇 |
1996年 | 40篇 |
1995年 | 33篇 |
1994年 | 24篇 |
1993年 | 32篇 |
1992年 | 68篇 |
1991年 | 76篇 |
1990年 | 76篇 |
1989年 | 53篇 |
1988年 | 45篇 |
1987年 | 70篇 |
1986年 | 57篇 |
1985年 | 35篇 |
1984年 | 41篇 |
1983年 | 47篇 |
1982年 | 21篇 |
1981年 | 21篇 |
1980年 | 20篇 |
1979年 | 25篇 |
1977年 | 17篇 |
1973年 | 14篇 |
1971年 | 13篇 |
1970年 | 15篇 |
1969年 | 16篇 |
排序方式: 共有6877条查询结果,搜索用时 0 毫秒
81.
82.
83.
84.
85.
86.
Hon Mei Yee Chua Xin Yun Premakumar Chandini Menon Mohamed Shah Noraida 《International journal of clinical pharmacy》2020,42(3):948-955
International Journal of Clinical Pharmacy - Background Drug-related problems are relatively common among hospitalised patients and may be detrimental to patients and even increase healthcare... 相似文献
87.
Diabetic peripheral neuropathy in people with type 2 diabetes is poorly managed because of its insidious onset, delayed diagnosis and more complex aetiology resulting from the contribution of not only hyperglycaemia, but also ageing, hyperlipidaemia, hypertension and obesity. Because there is no US Food and Drug Adminstration-approved disease-modifying therapy for diabetic peripheral neuropathy, the key to ameliorating it in type 2 diabetes has to be through earlier diagnosis and timely multi-factorial risk factor reduction. The management of painful diabetic peripheral neuropathy also requires a detailed appraisal of the choice of therapy, taking into account efficacy, patient wishes, comorbidities, side effect profile and potential for abuse. 相似文献
88.
BackgroundABO-incompatible kidney transplantation (ABOiKT) has been accepted as a viable and cost-effective modality with outcomes comparable to ABO-compatible transplants, but there is a concern regarding higher infectious complications in ABOiKT because of the heightened immunosuppression.The desensitization protocol normally includes antibody removal, B cell depletion by rituximab (RTX), and immunomodulation with intravenous immunoglobulin. Efforts have been made over the years to decrease the dose of RTX in an effort to decrease the infective complications. There is limited literature about the minimum effective dose of RTX, which can cause an effective B cell depletion. This prospective study was designed to correlate the RTX dose with peripheral absolute B cell count, graft function, graft and patient survival, and infective complications.MethodsThis study included 52 adult ABOiKT recipients with anti-A/B antibody titer up to a maximum of 1:512. The participants were divided into 2 groups of 26 each according to the RTX dosage used: Group A received 100 mg/patient, and Group B received 200 mg/patient. RTX was given 14 days prior to transplant after B cell measurement by flow cytometry. The outcomes were compared after 1 year of follow-up.ResultsBoth the dosages effectively depleted the absolute B cell count. Although patient survivals, graft survival, graft function, acute rejection episodes, and post-transplant hospital stay were similar in both groups, infective complications were significantly higher in group B.ConclusionA low dose (100 mg/patient) of RTX produces effective depletion of B cells while lowering the infective complications in ABOiKT. 相似文献
89.
90.